Jubilant Ingrevia reported a healthy performance in Q4 FY26, with revenue rising 12 per cent year-on-year and EBITDA increasing 11 per cent year-on-year. The company said strong execution, resilient demand and effective handling of Middle East disruptions supported its quarterly performance.

The company highlighted that it faced no force majeure and recorded zero production loss during the Middle East crisis. It also achieved successful dispatch from its newly constructed Agro CDMO facility and completed the acquisition of Remidex to accelerate growth in its Human Nutrition business.

The Board recommended a final dividend of Rs 2.50 per share, taking the total FY26 dividend to Rs 5 per share. The company said demand across the chemical industry remains resilient, with volumes growing and pricing firming up due to higher crude-linked costs.

Pharmaceuticals continued to support growth through strong volumes and steady demand, while the agrochemicals business saw strong export visibility and price increases. Nutrition and Personal Care markets also grew, driven by Niacinamide and demand across Feed and Cosmetics.

For FY27, Jubilant Ingrevia expects growth to be led by Specialty Chemicals and Nutrition, supported by recovery in Acetyls. The company also said construction of its Gajraula Multi Purpose Plant is progressing well and will strengthen its CDMO growth roadmap.